搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
3 天
GSK报告年轻成年人Arexvy疫苗数据令人鼓舞
全球医疗保健公司GSK plc (LSE/NYSE: GSK)今天宣布了正在进行的临床试验的初步数据,这些数据表明其呼吸道合胞病毒(RSV)疫苗Arexvy可能对更广泛的成年人群有效。 目前,Arexvy已在50多个国家获准用于60岁及以上人群,在美国和欧洲获准用于50-59岁高风险人群。新数据可能将RSV保护范围扩大到18-49岁有基础疾病的成年人和免疫功能低下的成年人。 III期临床试验(NC ...
生物谷
5 天
葛兰素史克公布呼吸道合胞病毒(RSV)疫苗Arexvy积极数据,疫苗保护 ...
Arexvy是全球首款RSV疫苗,其获批基于在60岁及以上成人中的显著效力,包括因患有某些基础疾病的高风险人群。今日公布的结果显示,接种GSK单剂RSV疫苗在三个RSV完整流行季中的累积保护效力具有临床意义。与安慰剂相比,该疫苗对于RSV引发的下呼吸 ...
5 天
3项关于RSV疫苗/药物最新数据公布,涉及辉瑞Abrysvo、GSK Arexvy......
近日,在洛杉矶举行的2024年美国感染性疾病周(IDWeek)会议期间,默沙东和辉瑞分别展示了其针对呼吸道合胞病毒(RSV)的预防药物新数据,并宣称这些药物对预防感染及相关住院具有强大的保护效果。IDWeek是全球感染病学领域的顶级学术盛会,每年吸引 ...
1 天
GSK Q3 Earnings Preview: Shingrix And Arexvy Make The Stock A 'Strong Buy'
GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...
The Pharma Letter
2 天
New data for GSK’s Arexvy RSV vaccine
US pharma major GSK yesterday announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant ...
来自MSN
3 天
GSK’s Arexvy Vaccine Shows Promise for Broader Use
GlaxoSmithKline (GB:GSK) has released an update. GSK has announced promising new data for its RSV vaccine, Arexvy, which ...
2 天
GSK reports preliminary data for AREXVY
GSK (GSK) announced new preliminary data for AREXVY in adults aged 18-49 at increased risk for lower respiratory tract disease, LRTD, caused by ...
17 天
RSV疫苗的市场前景变了吗?
此外,近日GSK公布其RSV疫苗在预防60岁以上老年人3年(3个完整流行季)的保护效力,累积保护效力为63%,然而却呈现显著的下降趋势——从第1年的83%到第2年的56%再到第3年的48%,而Arexvy的初始效力在三款疫苗中已是佼佼者。
Monthly Prescribing Reference
3 天
Arexvy Looks Promising for RSV Protection in Younger At-Risk and Immunocompromised Adults
Arexvy is currently approved for active immunization for the prevention of LRTD caused by RSV in individuals 60 years of age and older, and those 50 to 59 years of age who are at increased risk for ...
3 天
Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging ...
GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...
FiercePharma
3 天
GSK answers Pfizer's RSV approval with data targeting matching nod in younger adults
“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...
2 天
Graham Parry Recommends Sell Rating for GlaxoSmithKline Due to Concerns Over Arexvy Vaccine ...
Bank of America Securities analyst Graham Parry has maintained their bearish stance on GSK stock, giving a Sell rating on October 9. Graham ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈